Cambridge UK, 21 January, 2015: Abcam plc, a global leader in the supply of life science research tools, today announces that it has entered into a definitive agreement to acquire the entire issued share capital of Firefly BioWorks Inc (“Firefly”) (“the Acquisition”) on a cash-free/debt-free basis for £18.5m ($28.0m). The consideration, which is payable in cash on completion, will be funded from Abcam’s existing resources .
Firefly has developed a novel multiplex assay platform for the detection of biomarkers, based on a microfabrication technology developed by the founders at Massachusetts Institute of Technology and has developed its first product for detection of microRNAs (miRNAs). Firefly has 15 employees and is based in Cambridge, Massachusetts.
The Acquisition fits well with Abcam’s strategy outlined in September to establish new growth platforms and supports the Company’s mission to enable scientists to discover more. Firefly will strengthen [click to continue…]
Dr. Davide Marini, co-founder and Chief Executive Officer of Firefly BioWorks announced today the creation of the Firefly Frontiers Grant:
“We are excited to provide financial support to researchers for expanding the horizons of microRNA research. We encourage applicants to explore high-impact questions and those high-risk explorations that would not be normally funded through a traditional academic route”.
The Firefly Frontiers Grant is a $10,000 award in products and services to support exploratory studies in the area of microRNAresearch. It is open to principal investigators, postdoctoral and graduate students in academic and non-profit research institutions. The company’s flagship product, FirePlex™ miRSelect, enables high-throughput and targeted microRNA profiling on a flow cytometer. FirePlex™ miRSelect scales easily [click to continue…]
Firefly BioWorks is a startup company introducing an innovative technology platform for multiplexed quantification of biomolecules. Their products offer simultaneous detection of many targets per sample with minimal hands-on time. The assay is designed to work on standard flow cytometers and takes 4 hours from experiment to data.
The company is launching an Early Access program for owners of benchtop cytometers and are looking for scientists interested in microRNA profiling. Participants will receive a 100-assay kits free of charge, in exchange for feedback on robustness and usability.
Details are available at:
Incoming search terms for this article: